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Background: We previously have shown that chronic kidney disease (CKD) is associated with cardiovascu-
lar and all-cause mortality in community-dwelling people 75 years and older. The present study addresses the
hypothesis that CKD is associated with a higher rate of hospital admission at an older age.
Study Design: Cohort study.
Setting & Participants: 15,336 participants from 53 UK general practices underwent comprehensive health
assessment between 1994 and 1999.
Predictor: Data for estimated glomerular filtration rate (eGFR, derived from creatinine levels using the CKD
Epidemiology Collaboration [CKD-EPI] study equation) and dipstick proteinuria were available for 12,371
participants.
Outcomes: Hospital admissions collected from hospital discharge letters for 2 years after assessment.
Measurements: Age, sex, cardiovascular risk factors, possible biochemical and health consequences of
kidney disease (hemoglobin, phosphate, and albumin levels; physical and mental health problems).
Results: 2,310 (17%) participants had 1 hospital admission, and 981 (7%) had 2 or more. After adjusting for
age, sex, and cardiovascular risk factors, HRs were 1.66 (95% CI, 1.21-2.27), 1.17 (95% CI, 0.95-1.43), 1.08
(95% CI, 0.90-1.30), and 1.11 (95% CI, 0.91-1.35) for eGFRs 30, 30-44, 45-59, and 75 mL/min/1.73 m2,
respectively, compared with eGFRs of 60-74 mL/min/1.73 m2 for hospitalizations during 6 months of
follow-up. HRs were weaker for follow-up of 6-18 months. Dipstick-positive proteinuria was associated with an
increased HR throughout follow-up (HR, 1.29 [95% CI, 1.11-1.49], adjusting for cardiovascular risk factors).
Dipstick-positive proteinuria and eGFR 30 mL/min/1.73 m2 were independently associated with 2 or more
hospital admissions during the 2-year follow-up. Adjustment for other health factors and laboratory measure-
ments attenuated the effect of eGFR, but not the effect of proteinuria.
Limitations: Follow-up limited to 2 years, selection bias due to nonparticipation in study, missing data for
potential covariates, and single noncalibrated measurements from multiple laboratories.
Conclusions: The study indicates that community-dwelling older people who have dipstick-positive protein-
uria and/or eGFR30 mL/min/1.73 m2 are at increased risk of hospitalization.
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hospitalization; older people.Chronic kidney disease (CKD) is a major healthproblem and is associated with cardiovascular
and all-cause mortality.1-3 There are few data about
the overall effects of CKD on morbidity and overall
health outcomes in the general population. A large
study in the United States has shown that for those
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664who are insured, individuals with CKD appear to be at
higher risk of later hospitalization.2 However, such a
study has a number of limitations. In particular,
assessment of kidney function was not available for
the entire population, but was measured selectively
in people who had a clinical indication. This means
that people included in the study potentially were
unrepresentative of the population, making results
difficult to generalize. In addition, such database
studies have limited data for confounding and ex-
planatory factors.
In the United Kingdom, there are limited data for
hospital admissions for CKD. Using a large study
of older people living in the community, we previ-
ously have shown that CKD is associated with a
high burden of comorbid conditions4 and higher
risk of death that was independent of concurrent
comorbid conditions and conventional cardiovascu-
lar risk factors.1 In the present article, we report
results for the association of CKD with rate of
hospital admission.
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CKD and Hospitalizations in Older PeopleMETHODS
StudyDesign
We used data from a cluster randomized trial of older people in
the setting of general practice (the Medical Research Council
[MRC] Study of Multidimensional Assessment of Older People).
The study protocol and main results have been reported previ-
ously.5,6 In brief, this trial compared 2 methods of multidimen-
sional assessment (universal vs targeted assessment) in people 75
years and older registered in 106 general practices from the MRC
General Practice Research Framework in England, Wales, and
Scotland selected to be representative of the UK general practice
standardized mortality ratios and Jarman deprivation score (catego-
rized into low, middle, and high scores).7 All patients 75 years or
older registered with the practices were eligible and invited to
participate unless they were resident in long-stay hospitals or
nursing homes or had a terminal illness. The trial was approved by
relevant local ethics committees. This report uses data from the 53
practices in the universal arm of the trial because in this arm, all
patients were offered an in-depth health assessment, including a
routine blood test. In the universal arm, 15,336 of 20,934 (73.2%)
participants attended for the assessment; nonresponders were older
and more likely to be women.5
DataCollected atAssessment
Assessments were conducted in 1994-1999 and carried out by
nurses trained in the study methods and assessments following a
structured questionnaire and protocol.5
Patients’ height, weight, waist and hip circumferences, and
blood pressure (average of 2 measurements each) were measured.
A nonfasting blood sample was obtained for a biochemical screen
that included serum creatinine, urea, potassium, albumin, calcium,
phosphate, bilirubin, alkaline phosphatase, aspartate aminotransfer-
ase, and urate and a full blood cell count (hemoglobin, white blood
cell count, and platelets). Urine dipstick for protein, glucose, and
blood was performed, and if positive for protein, a midstream urine
sample was obtained. Sociodemographic information, self-re-
ported medical history, lifestyle, and medication data were ob-
tained using nurse interview. Medication data were derived from
participants bringing their medicines to the assessment, and drugs
were coded into broad classes using the British National Formu-
lary chapter headings. Diabetes was classified according to self-
report of a medical diagnosis, use of antidiabetic medication, or the
presence of a high random blood glucose level. Participants were
asked about alcohol consumption, smoking history, and perception
of physical activity. Activities of daily living (ADLs) were catego-
rized by the number of dependencies for 8 activities (washing,
dressing, cutting toe nails, cooking, shopping, doing light house-
work, walking 50 yards, and going up and down stairs and steps).
We defined full or partial dependency as being unable to perform 2
or more ADLs. A score 24 on the Mini-Mental State Examina-
tion8 was considered to indicate cognitive impairment, and a
score 5 on the Geriatric Depression Scale,9 significant depres-
sion. Other variables included self-reported history of cancer,
unexpected weight loss of more than half a stone (1/2 stone 
3.175 kg), and history of falls in last 6 months (2 vs2).
Kidney Function
Of 45 local laboratories to which serum samples were sent, 37
used the modified Jaffé method and 7 used an enzymatic method
for serum creatinine (in 1, the method was unknown).
The CKD Epidemiology Collaboration (CKD-EPI) Study equa-
tion10,11 was used to calculate estimated glomerular filtration rate
(eGFR) and categorized into eGFR groups12 of75, 60-74, 45-59,
30-44, 30 mL/min/1.73 m2 using nonstandardized serum creati-
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standardized and nonstandardized creatinine in the Modification of
Diet in Renal Disease [MDRD] Study laboratory).13 Only those
who had dipstick data and no evidence of urinary tract infection on
the midstream urine sample were defined as having available urine
dipstick data. Dipstick proteinuria was categorized as none/trace
versus proteinuria (,, and).
Outcomes
Information for hospital admissions (defined as a stay of at least
1 night) for a 2-year period after the date of assessment was
collected from the hospital discharge letter extracted from the
practice records. Diagnostic codes for hospital admission were
summarized using International Classification of Diseases, Tenth
Revision chapter headings as circulatory (I00-I99), cancer or
diseases of the blood system (C00-D89), of infectious origin
(A00-B99, L00-L08, K65, M00-M03, and J00-J22), or other
causes of hospital admissions. Multiple causes were allowed.
Study participants were registered with the Office for National
Statistics for mortality follow-up (date and cause of death).
DataAnalysis
Data analyses were performed using Stata, version 11 (www.
stata.com). Crude associations for eGFR and dipstick proteinuria
with baseline criteria (using 2 tests and tests for trend as appropri-
ate) and for hospitalization rates (with corresponding 95% confi-
dence intervals [CIs]) were calculated. We censored participants at
death (if it occurred outside the hospital) or the end of the 2-year
follow-up after the health assessment.
A Cox proportional hazards model was used to model the
outcome of time to first hospitalization after the baseline assess-
ment. The proportional hazards assumption of the Cox hazard
model did not hold for the entire follow-up of 2 years because there
was a time-varying effect of eGFR, age, and sex, which changed
rapidly within the first few months. In other words, there were
strong selection effects over time that led to a changing hazard
ratio (HR) dependent on the time of follow-up. Follow-up time
therefore was divided into 2 periods (or time bands) for each
patient: the first 6 months after the baseline assessment and the
period from 6 months to 2 years (the end of follow-up). Cox
proportional hazard models were fitted separately for the time from
the start of the study up to 6 months and separately from 6 months
to 24 months for those who were not hospitalized within 6 months
and were alive (with baseline factors and measurements carried
forward to the 6-month start).
All models were adjusted for the effect of age using 4 strata with
cutoff points at ages 80, 85, and 90 years (model 1 in tables). We
tested for interactions between eGFR and dipstick proteinuria and
for eGFR and sex by fitting the respective interaction terms in the
age-adjusted models and performing Wald test for exclusion of all
interaction terms (in both the 6-month and 6- to-24 month fol-
low-up cohorts). Model 2 adjusted for socioeconomic status,
comorbid conditions, cardiovascular risk, or use of cardiovascular
drugs. Variables were Jarman score, smoking status (current, ex-,
or never smoker), alcohol use (never , ex-, and current drinker),
self-reported physical activity (very active, fairly, not very, and not
at all), waist-to-hip ratio (sex-specific quintiles), and comorbid
conditions using self-reported history of cardiovascular disease
(CVD; heart attack or stroke) and diabetes. Hypertension was
modeled separately as physician-diagnosed hypertension, average
blood pressure 140/90 mm Hg, or antihypertensive drug use.
Cardiovascular drugs were statins or aspirin. We adjusted for
angiotensin-converting enzyme–inhibitor and angiotensin II recep-
tor blocker use separately from other antihypertensive agents. We
ran models 1 and 2 separately for both eGFR and dipstick protein-
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included.
We then added laboratory measurements (model 3) and other
health measures (model 4) to investigate their role in the observed
associations. Hemoglobin and phosphate levels were categorized
as quintiles for each sex, and albumin, as quintiles for each sex and
assay type. Other health measures were Mini-Mental State Exami-
nation scores (23 vs23), Geriatric Depression Scale score (5
vs5), overall health perception (poor vs not poor), and ADLs.
For those hospitalized, we derived separate dummy variables for
the presence of infectious, cancer, cardiocirculatory, or other
causes for hospitalization. Logistic regression analyses were car-
ried out for the odds for specific causes of hospitalization (relative
to not having this cause) as a function of measurements preceding
that hospitalization (adjusted for age and sex). Secondary analysis
was conducted for the association of CKD with total number of
admissions (categorized as 0, 1, or 2) during follow-up using a
multinomial logistic regression. In all models, robust standard
errors were calculated to account for the study design of 53
practices from which participants were recruited.
RESULTS
CrudeAssociationsWith SubsequentHospitalization
For 13,177 of 15,336 (86%) participants who com-
pleted the in-depth assessment, eGFR was calculated.
Missing data included patient refusal of phlebotomy,
poor veins, lost blood sample, or unknown. During
the 2-year follow-up, 3,291 of 13,177 (25%) partici-
pants with eGFR data had at least 1 hospital admis-
sion; 2,310 (17%) had only 1 admission and 981 (7%)
had 2 or more admissions. For those hospitalized at
least once, the next admission occurred within a
median of 98 (25th-75th percentile, 42-225) days.
There were 12,371 participants who had both eGFR
and dipstick proteinuria data. Six participants died on
the day of admission to the hospital, and 2,279 died
after being admitted to the hospital. There were 999
patients who died within 2 years of follow-up without
entering the hospital; these were censored for the
analysis at their death date.
Selected baseline characteristics and their associa-
tions with eGFR and proteinuria are listed in Table 1.
Associations of baseline characteristics with subse-
quent hospital admissions are listed in Table 2. Hospi-
talization rates increased with increasing age, and
men were more likely to be hospitalized than women.
When investigating causes of admissions, 23.2% of
all admissions were for circulatory reasons, 14.2%
had infections as a contributing cause, and 11.6% had
cancer or blood-related diseases as a contributing
cause.
Associations of eGFRandProteinuriaWith
SubsequentHospitalization
Both decreasing categories of eGFR and dipstick-
positive proteinuria had higher crude hospitalization
rates (Table 2). Hospitalization rate ratios (age ad-
justed) stratified by sex and dipstick proteinuria re-
666sults are listed in Table 3. For those hospitalized, there
was no evidence for a trend across eGFR categories to
have more infectious disease (P  0.8) or cancer
diagnoses (P  0.5; adjusted for age and sex). How-
ever, for those hospitalized, in age- and sex-adjusted
analyses, there was a trend (P 0.001) for those with
lower eGFRs to have more hospitalizations related to
CVD, with odds ratios (ORs) of 1.86 (95% CI, 1.19-
2.92), 1.58 (95% CI, 1.25-1.99), 1.29 (95% CI, 1.03-
1.62), and 0.91 (95% CI, 0.72-1.15) for eGFRs 30,
30-44, 45-59, and75 mL/min/1.73 m2, respectively,
compared with eGFRs of 60-74 mL/min/1.73 m2.
These associations were not confounded by dipstick
proteinuria, which was not associated with infections,
cancer, or circulatory reasons (data not shown).
Subsequent analyses listed in Table 4 were based
on people with complete information for confounding
variables (n  10,977); results for analyses with all
data with varying totals for each model are very
similar (data not shown). Adjusting for age and sex of
participants, we found a strong effect of eGFR 30
mL/min/1.73 m2, which was stronger in the first 6
months of follow-up compared with the subsequent
18 months (model 1). In age-adjusted analysis, there
was no evidence for an interaction of eGFR and sex in
up to 6 months’ follow-up (P  0.7) and during the
subsequent 18 months of follow-up (P  0.8). The
association of eGFR 30 mL/min/1.73 m2 with hos-
pitalization attenuated, but remained significant, when
adjusting further for all cardiovascular risk factors
and underlying CVD, as well as Jarman score (model
2). HRs for eGFR 30 mL/min/1.73 m2 during the
first 6-month period were confounded weakly by
dipstick positivity. There was no evidence for an
interaction of eGFR and dipstick positivity in up to 6
months of follow-up (P  0.7) and during the subse-
quent 18 months of follow-up (P 0.6). There was no
evidence of time-dependent effects of dipstick positiv-
ity, and the age- and CVD risk–adjusted HR was 1.29
(95% CI, 1.11-1.49) for the total 2-year follow-up.
We then adjusted the model with both eGFR and
proteinuria for hemoglobin, albumin, and phosphate
levels (model 3), and the association of eGFR 30
mL/min/1.73 m2 was attenuated further by 12% (for
eGFR 30 mL/min/1.73 m2; HR, 1.44 [95% CI,
1.04-1.98] in the first 6 months and 1.06 [95% CI,
0.81-1.40] in the subsequent 18 months; the reference
group is eGFR of 60-74 mL/min/1.73 m2; other data
not shown). Adjustment for hemoglobin, albumin,
and phosphate levels did not appreciably alter the
effects of dipstick proteinuria in the same models
(HR, 1.23 [95% CI, 0.97-1.57] in the first 6 months
and HR, 1.28 [95% CI, 1.06-1.53] in the subsequent
18 months).
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CKD and Hospitalizations in Older PeopleTable 1. Baseline Characteristics for 12,371 Participants With Both eGFR and Urine Data
eGFR (mL/min/1.73 m2)
P for
Trend
Proteinuria
Pa<30 30-44 45-59 60-74 >75 Present Absent
No. of participants 396 2,029 666 3,787 1,493 922 11,449
Age (y) 84.1  5.2 83.1  5.0 81.4  4.5 80.1  4.1 79.4  3.7 0.001 81.3  4.7 81.1  4.6 0.08
Women 288 (73) 1,452 (72) 3,046 (65) 2,036 (54) 713 (48) 0.001 494 (54) 7,041 (62) 0.001
Jarman scores 0.001a 0.00
Low 113 (29) 596 (29) 1,328 (28) 1,254 (33) 604 (40) 317 (34) 3,578 (31)
Middle 110 (28) 562 (28) 1,342 (29) 1,027 (27) 286 (19) 202 (22) 3,125 (27)
High 173 (44) 871 (43) 1,996 (43) 1,506 (40) 603 (40) 403 (44) 4,746 (41)
History of DM 42 (11) 190 (9) 314 (7) 273 (7) 138 (9) 0.5 108 (12) 849 (7) 0.001
History of HTN 201 (51) 817 (41) 1,617 (35) 1,128 (30) 402 (27) 0.001 393 (43) 3,772 (33) 0.001
History of MI or stroke 142 (36) 480 (24) 779 (17) 583 (16) 169 (11) 0.001 191 (21) 1,962 (17) 0.007
Smoking history 0.001a 0.04
Nonsmoker 169 (43) 879 (43) 1,941 (42) 1,278 (34) 513 (34) 321 (35) 4,459 (39)
Ex-smoker 190 (48) 938 (46) 2,227 (48) 2,043 (54) 755 (51) 491 (53) 5,662 (50)
Current smoker 37 (9) 206 (10) 485 (10) 456 (12) 222 (15) 110 (12) 1,296 (11)
Alcohol use 0.001a 0.1
Never 83 (22) 416 (21) 718 (16) 431 (12) 180 (12) 150 (17) 1,678 (15)
Ex 19 (5) 157 (8) 253 (6) 219 (6) 63 (4) 62 (7) 649 (6)
Current 281 (73) 1,403 (71) 3,568 (79) 3,039 (82) 1,214 (83) 682 (76) 8,823 (79)
Waist-to-hip ratio
quintileb
0.006a 0.1
1 52 (14) 344 (18) 883 (20) 753 (21) 318 (22) 169 (19) 2,181 (20)
2 68 (19) 344 (18) 923 (21) 706 (20) 291 (21) 152 (17) 2,180 (20)
3 75 (21) 380 (20) 862 (20) 731 (20) 282 (20) 183 (21) 2,147 (20)
4 86 (24) 414 (22) 852 (19) 724 (20) 266 (19) 193 (22) 2,149 (20)
5 79 (22) 396 (21) 874 (20) 677 (19) 260 (18) 189 (21) 2,097 (20)
BP140/90 mm Hg 232 (60) 1,263 (63) 3,047 (66) 2,391 (64) 901 (61) 0.3 617 (67) 7,217 (64) 0.03
Antihypertensive use 204 (52) 859 (43) 1,596 (35) 1,087 (29) 390 (26) 0.001 360 (40) 3,776 (34) 0.001
Statin use 6 (2) 16 (1) 35 (1) 23 (1) 5 (0) 0.02 11 (1) 74 (1) 0.05
NSAID use 65 (17) 275 (14) 487 (11) 405 (11) 156 (11) 0.001 109 (12) 1,279 (11) 0.6
ACEi/ARB use 77 (20) 296 (15) 437 (10) 219 (6) 94 (6) 0.001 100 (11) 1,023 (9) 0.06
Aspirin use 104 (27) 462 (23) 892 (19) 673 (18) 218 (15) 0.001 191 (21) 2,158 (19) 0.2
Albumin quintilec 0.001a 0.2
1 89 (23) 305 (15) 578 (12) 522 (14) 255 (17) 126 (14) 1,623 (14)
2 77 (20) 401 (20) 877 (19) 675 (18) 314 (21) 188 (21) 2,156 (19)
3 55 (14) 336 (17) 776 (17) 665 (18) 277 (19) 150 (16) 1,959 (17)
4 70 (18) 467 (23) 1,065 (23) 834 (22) 268 (18) 180 (20) 2,524 (22)
5 99 (25) 496 (25) 1,338 (29) 1,052 (28) 365 (25) 272 (30) 3,078 (27)
Hemoglobin quintileb 0.001a 0.00
1 182 (47) 523 (26) 798 (18) 534 (14) 227 (15) 213 (23) 2,051 (18)
2 72 (19) 440 (22) 805 (18) 681 (18) 254 (17) 175 (19) 2,077 (19)
3 46 (12) 342 (17) 881 (19) 756 (20) 315 (22) 163 (18) 2,177 (19)
4 51 (13) 362 (18) 1,041 (23) 892 (24) 370 (25) 181 (20) 2,535 (23)
5 33 (9) 322 (16) 1,031 (23) 844 (23) 299 (20) 175 (19) 2,354 (21)
Phosphate quintileb 0.001a 0.4
1 41 (11) 336 (18) 865 (20) 676 (20) 266 (19) 153 (18) 2,031 (19)
2 49 (13) 331 (18) 849 (20) 747 (22) 287 (21) 185 (22) 2,078 (20)
3 57 (15) 340 (18) 828 (19) 708 (20) 270 (20) 154 (18) 2,049 (20)
4 81 (22) 377 (20) 877 (21) 710 (21) 286 (21) 165 (20) 2,166 (21)
5 146 (39) 479 (26) 844 (20) 616 (18) 268 (19) 186 (22) 2,167 (21)
Partially/fully
dependent
225 (57) 847 (42) 1,311 (28) 834 (22) 309 (21) 0.001 292 (32) 3,234 (28) 0.03(Continued)
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Nitsch et alFurther adjustments for Mini-Mental State Exami-
nation scores, Geriatric Depression Scale scores,
overall health perception, and ADLs attenuated the
association of eGFR 30 mL/min/1.73 m2 with
hospitalization (HR, 1.28 [95% CI, 0.91-1.80] for
the first 6 months and HR, 1.01 [95% CI, 0.76-1.34]
for the subsequent 18 months), whereas in the same
analysis, the association of proteinuria with hospital-
ization remained very similar (HR, 1.21 [95% CI,
0.95-1.55] in the first 6 months and HR, 1.27 [95% CI,
1.05-1.53] for the subsequent 18 months; model 4;
other data not shown).
Associations of eGFRandProteinuriaWithNumber
ofHospitalizations
Compared with eGFR of 60-74 mL/min/1.73 m2,
eGFR categories of 30-44 and 30 mL/min/1.73 m2
were associated with increased ORs for 2 or more
hospitalizations during the 2-year follow-up. For those
with eGFR 30 mL/min/1.73 m2 in particular, there
was a more than doubled OR (Table 5). Adjustments
for cardiovascular risk factors at baseline attenuated
associations of eGFR with number of hospitaliza-
tions, with an increased OR remaining for only eGFR
30 mL/min/1.73 m2 and 2 or more admissions.
Dipstick-positive proteinuria (not adjusted for eGFR)
was associated with multiple hospitalizations during
follow-up; adding potential cardiovascular confound-
ing variables did not attenuate the association appre-
ciably. In a model with both proteinuria and eGFR, we
found that both dipstick-positive proteinuria and eGFR
Table 1 (Cont’d). Baseline Characteristics for
eGFR (mL/min/1.73 m
<30 30-44 45-59
Cognitive impairment 98 (26) 453 (23) 770 (17)
Depressed 37 (9) 187 (9) 331 (7)
Health perception
poor
16 (4) 40 (2) 69 (1)
Physically active
Very 41 (10) 406 (20) 1,284 (28) 1
Fairly 183 (47) 1,014 (50) 2,418 (52) 1
Not very 128 (33) 474 (24) 786 (17)
Not at all 41 (10) 118 (6) 156 (3)
2 falls at home in
last 6 mo
55 (14) 205 (10) 365 (8)
Note: Values shown as mean  standard deviation or numbe
shown. Proteinuria presence assessed using dipstick positivity.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor;
mellitus; eGFR, estimated glomerular filtration rate; HTN, h
inflammatory drug.
a2 test for association.
bSex-specific.
cSex- and assay-specific.30 mL/min/1.73 m2 were associated independently
668with the odds of multiple hospitalizations during the
2-year follow-up, even after adjustment for CVD
(Table 5).
Laboratory parameters (hemoglobin, phosphate, and
albumin) attenuated the observed associations for
eGFR 30 mL/min/1.73 m2 (OR, 1.21 [95% CI,
0.79-1.85] for 2 or more hospitalizations compared
with none), whereas the effect for dipstick proteinuria
was completely unchanged (model 3). Additional ad-
justments for other health factors (model 4) attenuated
the association of number of hospitalizations with
eGFR 30 mL/min/1.73 m2 (OR, 1.16 [95% CI,
0.73-1.85] for 2 or more hospitalizations compared
with none), whereas the association with dipstick
proteinuria was unchanged (OR, 1.34 [95% CI, 1.04-
1.71] for 2 or more hospitalizations compared with
none).
DISCUSSION
Our results show that dipstick-positive proteinuria
is associated with an approximate 30% increased risk
of single and multiple hospitalizations during the 2
years after measurement. We found a strong associa-
tion of eGFR 30 mL/min/1.73 m2 with the short-
term incidence of hospitalization (6 months) and a
50% increase in odds of more than 1 admission. This
finding agrees with previous studies that examined
only eGFR.2,14 Our results indicate the potential im-
portance of dipstick testing and eGFR measurement
in the early identification of older people who are at
1 Participants With Both eGFR and Urine Data
P for
Trend
Proteinuria
Pa4 >75 Present Absent
14) 214 (15) 0.001 180 (20) 1,886 (17) 0.02
(6) 113 (8) 0.002 94 (10) 809 (7) 0.001
2) 35 (2) 0.5 23 (3) 199 (2) 0.1
0.001a 0.04
(32) 465 (31) 232 (25) 3,150 (28)
(51) 736 (50) 454 (50) 5,811 (51)
15) 213 (14) 191 (21) 1,957 (17)
(3) 70 (5) 38 (4) 455 (4)
(6) 125 (8) 0.001 85 (9) 888 (8) 0.1
rcentage); unless otherwise indicated, column percentages are
, angiotensin receptor blocker; BP, blood pressure; DM, diabetes
ension; MI, myocardial infarction; NSAID, nonsteroidal anti-12,37
2)
60-7
531 (
235
62 (
,186
,914
547 (
108
223
r (pe
ARB
ypertrisk of hospitalization.
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CKD and Hospitalizations in Older PeopleTable 2. Rates of Subsequent Hospital Admission According to
Selected Participants’ Baseline Characteristics
No.
Hospitalized
Hospitalization
Rate per 100
Person-Years
(95% CI) Pa
Age (y) 0.001
75-80 1,376 11.8 (12.1-13.5)
80-85 1,082 16.0 (15.0-16.9)
85-90 608 19.0 (17.5-20.6)
90 193 19.1 (16.6-22.0)
Sex 0.001
Male 1,390 16.8 (15.9-17.7)
Female 1,869 13.9 (13.3-14.5)
eGFR (mL/min/1.73 m2) 0.001
75 390 14.8 (13.4-16.3)
60-74 923 13.6 (12.8-14.5)
45-59 1,182 14.3 (13.5-15.2)
30-44 617 17.7 (16.4-19.2)
30 417 23.7 (20.2-27.9)
Proteinuriab 0.001
Negative 2,748 14.4 (13.9-15.0)
Positive 290 20.1 (17.9-22.5)
Missing 221 17.9 (15.7-20.4)
Jarman scores 0.001
Low 893 12.8 (12.0-13.7)
Middle 871 15.1 (14.1-16.1)
High 1,495 16.6 (15.7-17.4)
History of DM 0.001
No 2,945 14.6 (14.1-15.1)
Yes 314 19.6 (17.6-21.9)
History of HTN 0.3
No 2,107 14.8 (14.2-15.4)
Yes 1,121 15.4 (14.5-16.3)
History of MI or stroke 0.001
No 2,473 13.7 (13.1-14.2)
Yes 758 21.8 (20.3-23.4)
Smoking history 0.001
Nonsmoker 1,190 13.9 (13.2-14.8)
Ex-smoker 1,621 15.1 (14.3-15.8)
Current smoker 436 18.2 (16.6-20.0)
Alcohol use 0.2
Never 490 15.1 (13.9-16.5)
Ex 224 18.5 (16.3-21.1)
Current 2,461 14.7 (14.1-15.3)
Waist-to-hip ratio
quintilec
0.001
1 550 13.3 (12.2-14.4)
2 585 14.0 (12.9-15.2)
3 581 14.0 (12.9-15.2)
4 642 15.8 (14.7-17.1)
5 651 16.2 (15.0-17.5)(Continued)
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According to Selected Participants’ Baseline Characteristics
No.
Hospitalized
Hospitalization
Rate per 100
Person-Years
(95% CI) Pa
BP (mm Hg) 0.01
140/90 1,232 16.0 (15.1-16.9)
140/90 2,005 14.5 (13.8-15.1)
Antihypertensive use 0.002
No 2,060 14.5 (13.8-15.1)
Yes 1,160 16.2 (15.3-17.2)
Statin use 0.6
No 3,200 15.1 (14.5-15.6)
Yes 20 13.5 (8.7-21.0)
NSAID use 0.001
No 2,800 14.7 (14.2-15.3)
Yes 420 17.6 (16.0-19.4)
ACEi/ARB use 0.001
No 2,835 14.5 (14.0-15.0)
Yes 385 21.2 (19.2-23.4)
Hemoglobin quintilec 0.001
1 784 21.5 (20.0-23.0)
2 639 16.3 (15.1-17.6)
3 578 13.7 (12.7-14.9)
4 619 12.7 (11.7-13.7)
5 566 12.3 (11.3-13.4)
Phosphate quintilec 0.01
1 544 13.9 (12.8-15.1)
2 608 15.5 (14.3-16.8)
3 597 15.6 (14.4-16.9)
4 612 14.9 (13.7-16.1)
5 686 16.9 (15.7-18.3)
Albumin quintiled 0.001
1 554 19.4 (17.9-21.1)
2 624 15.1 (13.9-16.4)
3 559 15.1 (13.9-16.4)
4 695 14.4 (13.3-15.5)
5 793 13.1 (12.2-14.1)
Partially/fully dependent 0.001
ADL 2 1,972 12.3 (11.8-12.9)
ADL 2 1,281 22.4 (21.2-23.7)
Cognitive impairment 0.001
MMSE 23 660 18.7 (17.3-20.2)
MMSE 23 2,512 14.1 (13.6-14.7)
Depressed 0.001
GDS 5 2,882 14.4 (13.9-14.9)
GDS 5 327 22.2 (19.9-24.7)
Health perception 0.001
Not poor 3,121 14.7 (14.1-15.2)
Poor 109 36.3 (30.0-43.7)(Continued)
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Nitsch et alOther studies in the United States using health
insurance claims data have found broadly similar
results of an association of eGFR with risk of subse-
quent hospitalization.2,15 However, many people with
less severe degrees of CKD are not identifiable in US
Table 2 (Cont’d). Rates of Subsequent Hospital Admission
According to Selected Participants’ Baseline Characteristics
No.
Hospitalized
Hospitalization
Rate per 100
Person-Years
(95% CI) Pa
Physically active 0.001
Very 649 10.4 (9.6-11.2)
Fairly 1,568 14.0 (13.4-14.8)
Not very 800 23.2 (21.6-24.8)
Not at all 212 29.6 (25.8-33.8)
Falls at home in last 6
mo
0.001
2 2,878 14.3 (13.8-14.9)
2 366 23.3 (21.0-25.8)
Missing CV data 0.001
Yes 580 16.9 (15.6-18.4)
No 2,679 14.6 (14.1-15.2)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor;
ADL, activities of daily living; ARB, angiotensin receptor blocker;
BP, blood pressure; CI, confidence interval; CV, cardiovascular;
DM, diabetes mellitus; eGFR, estimated glomerular filtration
rate; GDS, Geriatric Depression Scale; HTN, hypertension; MI,
myocardial infarction; MMSE, Mini-Mental State Examination;
NSAID, nonsteroidal anti-inflammatory drug.
aTrend in rate ratio.
bMidstream urine positive.
cSex-specific.
dSex- and assay-specific. For albumin, 39 of 45 laboratories
used bromocresol green, the rest used bromocresol purple, and
quintiles were derived by assay and sex.
Table 3. Age-Adjusted Ratios of Hospital Admission Rates
Across Categories of eGFR in Men and Women Stratified by
Presence of Proteinuria
Proteinuria
eGFR
(mL/min/1.73 m2) Men Women
Absent 75 1.11 (0.94-1.31) 1.12 (0.92-1.35)
60-74 1.00 (reference) 1.00 (reference)
45-59 0.99 (0.86-1.13) 1.08 (0.95-1.23)
30-44 1.21 (0.99-1.47) 1.19 (1.03-1.39)
30 1.18 (0.76-1.85) 1.52 (1.18-1.95)
Present 75 0.73 (0.42-1.28) 1.09 (0.46-2.59)
60-74 1.00 (reference) 1.00 (reference)
45-59 0.64 (0.41-1.01) 1.23 (0.77-1.95)
30-44 0.92 (0.58-1.46) 2.19 (1.35-3.54)
30 1.21 (0.65-2.25) 2.91 (1.57-5.40)
Note: Values shown as rate ratio (95% confidence interval).
Mantel-Haenszel tests for interaction between sex and eGFR
and between eGFR and proteinuria were nonsignificant. Protein-
uria presence was assessed using dipstick.Abbreviation: eGFR, estimated glomerular filtration rate.
670claims databases, limiting their utility.16 In the United
Kingdom, to our knowledge, no community-based
study has investigated whether CKD increases the
risk of hospitalization.
It is unclear exactly what explains the associations
Table 4. Effects of Sequential Adjustments in Complete-Case
Subset of Data on Associations of eGFR and Proteinuria With
Subsequent Hospitalization
Model: Category
<6 mo
(n  10,977)
6-24 mo
(n  10,042)
Effect of eGFR Alone (not adjusted for proteinuria)
1: age, sex adjusted
eGFR75 1.11 (0.91-1.36) 1.04 (0.88-1.23)
eGFR 60-74 1.00 (reference) 1.00 (reference)
eGFR 45-59 1.11 (0.93-1.34) 1.01 (0.92-1.11)
eGFR 30-44 1.36 (1.11-1.65) 1.19 (1.01-1.41)
eGFR30 2.17 (1.59-2.96) 1.53 (1.18-1.99)
2: as above and adjusted
for CVD risk factorsa
eGFR75 1.11 (0.91-1.35) 1.08 (0.91-1.27)
eGFR 60-74 1.00 (reference) 1.00 (reference)
eGFR 45-59 1.08 (0.90-1.30) 0.97 (0.88-1.07)
eGFR 30-44 1.17 (0.95-1.43) 1.04 (0.89-1.21)
eGFR30 1.66 (1.21-2.27) 1.23 (0.95-1.59)
eGFR and Proteinuria Adjusted for Each Other
1: age, sex adjusted
eGFRb 75 1.11 (0.91-1.36) 1.04 (0.88-1.23)
eGFRb 60-74 1.00 (reference) 1.00 (reference)
eGFRb 45-59 1.11 (0.92-1.33) 1.00 (0.91-1.10)
eGFRb 30-44 1.34 (1.10-1.64) 1.18 (1.00-1.40)
eGFRb30 2.10 (1.54-2.85) 1.48 (1.14-1.93)
Proteinuriac 1.30 (1.02-1.66) 1.31 (1.07-1.60)
2: as above, and adjusted
for CVD risk factorsa
eGFRb 75 1.11 (0.91-1.35) 1.08 (0.91-1.28)
eGFRb 60-74 1.00 (reference) 1.00 (reference)
eGFRb 45-59 1.08 (0.90-1.30) 0.97 (0.88-1.07)
eGFRb 30-44 1.16 (0.95-1.42) 1.03 (0.88-1.20)
eGFRb30 1.62 (1.18-2.21) 1.20 (0.93-1.54)
Proteinuriac 1.26 (0.99-1.59) 1.28 (1.05-1.55)
Note: Values shown as hazard ratio (95% confidence interval).
eGFRs are given in mL/min/1.73 m2.
Abbreviations: CVD, cardiovascular disease; eGFR, esti-
mated glomerular filtration rate.
aIn addition to age and sex, model 2 was adjusted for Jarman
deprivation score (low, middle, and high), smoking status (cur-
rent, ex-, or never smoker), alcohol (never, ex-, and current
drinker), self-reported physical activity (very active, fairly, not
very, and not at all), waist-to-hip ratio (sex-specific quintiles), and
comorbid conditions using self-reported history of CVD (heart
attack or stroke) and diabetes. Hypertension was modeled sepa-
rately as physician-diagnosed hypertension, average blood pres-
sure 140/90 mm Hg, or use of antihypertensive drugs. Cardio-
vascular drugs were statins or aspirin. We adjusted for
angiotensin-converting enzyme inhibitors and angiotensin II re-
ceptor blockers separately from other antihypertensive agents.
beGFR adjusted for proteinuria.
cDipstick-positive proteinuria adjusted for eGFR.found. Rate ratios for eGFR across the total follow-up
Am J Kidney Dis. 2011;57(5):664-672
cAdjusted for eGFR.
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CKD and Hospitalizations in Older Peoplewere less marked for men than women (Table 3);
however, these rate ratios conceal variations in the
pattern of HRs during follow-up. Men, those who
were older, and those with lower eGFRs had higher
admission rates during the first few months of follow-
up. For this reason, we split the time into a short- (up
to 6 months) and long-term risk period (6-18 months).
Adjustment for concurrent CVD risk factors attenu-
ated the associations of eGFR 30 mL/min/1.73 m2
for the first 6 months of follow-up, suggesting that
cardiovascular risk factors may explain some (but not
all) associations. Adjustment for hemoglobin, phos-
phate, or albumin levels led to little attenuation of the
association of eGFR with time to hospitalization; in
contrast, there was more attenuation of the association
of eGFR with number of hospitalizations. Further
adjusting for health factors that indicate other aspects
of physical and mental health almost completely at-
tenuated the association of eGFR 30 mL/min/1.73
m2 with either rate or number of admissions. It there-
fore is possible that some of the association of eGFR
30 mL/min/1.73 m2 may be mediated through fac-
tors related to other health problems. No such attenua-
tion was observed for effects of dipstick proteinuria.
Our study derives from a representative sample of
the UK community-dwelling older population, with
systematic testing of serum creatinine and dipstick
proteinuria at baseline and systematic follow-up for
hospitalization during 2 years after these measure-
ments. Our findings are not applicable to people living
in nursing homes. Competing risks may have led to
underestimation of the true effect of eGFR and dip-
stick proteinuria on hospitalization. A quarter of par-
ticipants died during the follow-up period; 7% died
without being hospitalized, and 18%, with at least 1
admission. Because both low eGFR and proteinuria
are associated with higher risk of death, the risk of
hospital admission or multiple admissions in those
who died is different from those with low eGFR who
did not die (competing risks). We used Cox regression
rather than Poisson regression because of the limita-
tions of Poisson. A Poisson approach would have
assumed: (1) a constant rate of hospitalization during
a given observation period (and thus ignored the issue
of removal of those at highest risk of the hospitaliza-
tion or at risk of death during follow-up), and (2)
independence of risk of subsequent hospitalization
from having had previous hospitalizations.
We were able to collect hospital admission data in
only the first 2 years of follow-up and therefore our
study does not provide evidence for longer term risks
of hospital admission. Measurement errors may have
led to underestimation of associations of eGFR or
dipstick proteinuria There may be some interlabora-Table 5. Effects of Sequential Adjustments in Complete-Case
Subset of Data on Association of eGFR and Proteinuria (modeled
separately) With Hospital Admissions During 2-Year Follow-up
Model: Category
1 Admission
vs None
>2 Admissions
vs None
Effect of eGFR Alone
1: age, sex adjusted
eGFR 75 1.11 (0.93-1.34) 0.92 (0.67-1.27)
eGFR  60-74 1.00 (reference) 1.00 (reference)
eGFR  45-59 1.03 (0.91-1.17) 1.03 (0.85-1.26)
eGFR  30-44 1.21 (1.02-1.44) 1.31 (1.03-1.68)
eGFR 30 1.37 (1.02-1.84) 2.38 (1.63-3.48)
2: as above and adjusted for
CVD risk factorsa
eGFR 75 1.14 (0.94-1.38) 0.96 (0.70-1.33)
eGFR  60-74 1.00 (reference) 1.00 (reference)
eGFR  45-59 1.00 (0.88-1.13) 0.96 (0.78-1.19)
eGFR  30-44 1.07 (0.91-1.27) 1.04 (0.80-1.35)
eGFR 30 1.10 (0.81-1.49) 1.60 (1.08-2.36)
Effect of Proteinuria Alone
1: age, sex adjusted
Proteinuria absent 1.00 (reference) 1.00 (reference)
Proteinuria present 1.35 (1.09-1.68) 1.51 (1.17-1.95)
2: as above and adjusted for
CVD risk factorsa
Proteinuria absent 1.00 (reference) 1.00 (reference)
Proteinuria present 1.31 (1.06-1.62) 1.41 (1.12-1.76)
eGFR and Proteinuria Adjusted for Each Other
1: age, sex adjusted
eGFRb 75 1.12 (0.93-1.34) 0.92 (0.67-1.27)
eGFRb 60-74 1.00 (reference) 1.00 (reference)
eGFRb 45-59 1.03 (0.91-1.16) 1.03 (0.84-1.25)
eGFRb 30-44 1.20 (1.01-1.42) 1.29 (1.01-1.65)
eGFRb30 1.32 (0.98-1.78) 2.27 (1.55-3.32)
Proteinuria presentc 1.33 (1.06-1.66) 1.42 (1.11-1.82)
2: as above and adjusted for
CVD risk factorsa
eGFRb 75 1.14 (0.94-1.38) 0.97 (0.70-1.33)
eGFRb 60-74 1.00 (reference) 1.00 (reference)
eGFRb 45-59 1.00 (0.88-1.13) 0.96 (0.78-1.18)
eGFRb 30-44 1.06 (0.90-1.26) 1.03 (0.79-1.33)
eGFRb30 1.06 (0.78-1.44) 1.54 (1.04-2.27)
Proteinuria presentc 1.31 (1.06-1.62) 1.37 (1.10-1.71)
Note: N  10,977. Values shown as odds ratio (95% confi-
dence interval). eGFRs are given in mL/min/1.73 m2. Proteinuria
assessed as dipstick positivity.
Abbreviations: CVD, cardiovascular disease; eGFR, esti-
mated glomerular filtration rate.
aIn addition to age and sex, model 2 was adjusted for Jarman
deprivation score (low, middle, and high), smoking status (current, ex,
or never smoker), alcohol (never, ex-, and current drinker), self-
reported physical activity (very active, fairly, not very, and not at all),
waist-to-hip ratio (sex-specific quintiles), and comorbid conditions us-
ing self-reported history of CVD (heart attack or stroke) and diabetes.
Hypertension was modeled separately as physician-diagnosed hyper-
tension, average blood pressure140/90 mm Hg, or use of antihyper-
tensive drugs. Cardiovascular drugs were statins or aspirin. We ad-
justed for angiotensin-converting enzyme inhibitors and angiotensin II
receptor blockers separately from other antihypertensive agents.
beGFR adjusted for proteinuria.
tory variation in the creatinine measurement method,17
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Nitsch et alintroducing random variation in serum creatinine and
eGFR values. However, at high creatinine levels,
there is less variation17 and estimation formulas per-
form better,18 which means that errors associated with
risk estimates for eGFR 30 mL/min/1.73 m2 are
likely to be minimal. Similarly, dipstick proteinuria
readings are variable and less precise than urinary
protein or albumin-creatinine ratios or 24-hour urine
collections.19,20 Use of a midstream urine sample and
exclusion of patients with culture-positive urine may
have partially compensated for errors in dipstick pro-
teinuria. Of 20,934 older people invited to join this
study, 15,336 participated, of whom 12,371 had data
for both dipstick protein and eGFR. Complete data for
all potential confounders were available for only
10,799. Hence, there remains the possibility of selec-
tion bias in the fully adjusted analysis. However,
analyses of the larger sets of data (12,371) gave
virtually identical results. We cannot exclude the
possibility of confounding caused by unmeasured
factors, but this is a well-characterized data set that
enabled us to adjust for an extensive range of con-
founding variables, including socioeconomic depriva-
tion.
Our results show that both eGFR30 mL/min/1.73
m2 and dipstick proteinuria are associated with in-
creased risk of subsequent hospitalization. We found
no association at higher eGFRs or for those with
eGFR 75 mL/min/1.73 m2. There is considerable
interest in minimizing hospital admissions for older
people.21 Our results show that decreased kidney
function, particularly in the presence of proteinuria,
identifies older people at high risk of subsequent
hospital admission.
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